Skip Navigation

European Heart Journal 1984 5(11):913-918;
Copyright © 1984 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by ANTUNES, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ANTUNES, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1984 The European Society of Cardiology

Bioprosthetic valve replacement in children—long-term follow-up of 135 isolated mitral valve implantations*

M. J. ANTUNES

Division of Cardiothoracic Surgery, University of the Witwatersrand Johannesburg, South Africa

Received 10 July 1984; revised 12 September 1984; .

Abstract

From August 1976 to January 1980, 135 patients, age 20 years or younger (mean 13.7±3.46 years), received 37 Hancock, 4 Angell-Shiley and 94 Carpentier-Edwards prostheses as a mitral valve substitute. Only patients who had isolated mitral valve replacement were included in this study. All patients were in NYHA class III and IV and 22 had acute rheumatic valvulitis. Approximately half of the patients had mitral regurgitation.

Early mortality was 4.4% (6 patients). The cumulative follow up period was 356 patient-years. Thirty-eight patients died late (10.7% per patient year), of which 26 (7.3% per patient year) died of valve related causes. Sixty-four patients (18% per patient year) had mitral valve rereplacement for a degenerated bioprosthesis. Eleven patients with degenerating prostheses died witout surgery and 5 await reoperation. Hence, structural valve failure occurred in 80 instances (22.5% per patient year). Actuarial survival at 7 years was 50%. Complication-free valve survival was 15%. Only 7 patients (5.2%) remain with their original prostheses, free from degeneration.

Our experience confirms that bioprostheses have a prohibitive failure rate in children. Degenerating valves should be replaced early rather than late.

Key Words: Porcine bioprostheses • mitral valve replacement • rheumatic heart disease in children


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
K. R. Kanter, J. M. Forbess, and P. M. Kirshbom
Redo Mitral Valve Replacement in Children
Ann. Thorac. Surg., August 1, 2005; 80(2): 642 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Gunther, D. Mazzitelli, C. Schreiber, M. Wottke, S.-U. Paek, H. Meisner, and R. Lange
Mitral-valve replacement in children under 6 years of age
Eur. J. Cardiothorac. Surg., April 1, 2000; 17(4): 426 - 430.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.